Antibody based therapy in relapsed acute lymphoblastic leukemia.

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Outcomes for relapsed and refractory acute lymphoblastic leukemia (ALL) are historically poor.
• Targeted therapies, including monoclonal antibodies, have emerged as promising treatments.
• These agents offer new hope in both frontline and salvage settings.

Purpose of the Study:

• To discuss the role of monoclonal antibodies in treating relapsed and refractory ALL.
• To highlight the efficacy of blinatumomab and inotuzumab ozogamicin.
• To explore the use of these agents in monotherapy and combination regimens.

Main Methods:

• Review of clinical studies and approved uses of blinatumomab and inotuzumab ozogamicin.
• Analysis of their incorporation into salvage treatment protocols for ALL.
• Discussion of their use as monotherapy versus combination therapy with chemotherapy.

Main Results:

• Blinatumomab (anti-CD19/CD3) and inotuzumab ozogamicin (anti-CD22) have shown significant improvements in outcomes.
• These targeted agents have been approved for monotherapy use.
• Recent studies show successful incorporation into combination or sequential chemotherapy regimens.

Conclusions:

• Monoclonal antibodies are transforming the treatment of relapsed and refractory ALL.
• Their use in the salvage setting, both as monotherapy and in combination, offers improved management strategies.
• Continued research and application of these targeted agents are crucial for better patient outcomes.